Checked.be
Active
BE 0461.543.816Private limited company
PAMLAB
Rue de Libin,Smuid 27 ·6890 Libin, Belgium· 28 yrs active
Sector: Specialist medical practice
(86220)
Conclusion
PAMLAB has been active since 1997 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €834k and a net result of €-22k. Equity is shrinking by ~7% per year across the filed fiscal years. Its solvency ranks better than 95% of 16132 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Based on the State Gazette, CBE and 5 annual accounts.
Key figures
| Equity | €834k |
| Net result | €-22k |
| Better than sector | 95% |
| Active | 28 yrs |
Financial profile
62
/ 100
Strong profile, led by solvency.
All 5 axes are computed from data Checked has read.
Health
78
Profitability
0
Solvency
100
Growth
32
Stability
100
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
Long-established
Founded in 1997, 28 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
78
/ 100
Excellent
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€65k
estimate, not credit advice
Score history
93
2021
100
2022
83
2023
52
2024
78
2025
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 67.43 (≥ 1.5)
+10
Quick ratio
Quick ratio 67.43 (≥ 1.0)
+5
Leverage
Debt/equity 0.01 (< 1.0)
+10
Profitability
Negatieve ROE -3%
-10
Interest coverage
Interest coverage 3.9× (≥ 3×)
+8
Profit trend
Net profit up YoY
+5
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 31-08-2026 with the NBB · fiscal year 2025 · micro schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
declining
Equity: declining trend of ~7%/year over 5 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2025 · NACE 86, Human health activities · compared within the same schema type (micro schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 99.1% | 63.4% | |
| Net result | €-22k | €62k | |
| Equity | €834k | €132k | |
| Gross operating margin | €5k | €116k | |
| Total assets | €842k | €286k |
€1k
-
21-25
€-22k
+30.7%
21-25
€6k
+0.3%
21-25
€842k
-11.9%
21-25
€834k
-11.8%
21-25
€487k
-12.7%
21-25
€414
-87.3%
21-25
€89k
-25.3%
21-25
€7k
-22.0%
21-25
€7k
-22.0%
21-25
€12k
-56.9%
21-25
67.43
+11.8%
21-25
67.43
+11.8%
21-25
99.1%
+0.1%
21-25
0.01
-11.6%
21-25
-2.6%
+21.4%
21-25
-2.6%
+21.3%
21-25
3.86
-
21-25
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Deposit | micro schema | micro schema | micro schema | micro schema | micro schema |
| Revenue | - | - | - | - | - |
| EBITDA | €1k | €-1k | €39k | €382k | €327k |
| Net profit | €-22k | €-32k | €932 | €240k | €202k |
| Cash flow | €6k | €6k | €38k | €277k | €239k |
| Staff costs | - | - | - | - | - |
| Income taxes | - | €414 | €3k | €113k | €87k |
| Dividends | €89k | €120k | €35k | €168k | €161k |
| Total assets | €842k | €955k | €1.12M | €1.20M | €1.17M |
| Equity | €834k | €946k | €1.10M | €1.13M | €1.06M |
| Debt | €7k | €9k | €19k | €71k | €108k |
| of which ≤ 1y | €7k | €9k | €19k | €60k | €81k |
| of which > 1y | - | - | - | €12k | €27k |
| Working capital | €487k | €558k | €689k | €730k | €634k |
| Employees (FTE) | - | - | - | - | - |
Ratios (computed)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Current ratio | 67.43 | 60.33 | 36.79 | 13.26 | 8.84 |
| Quick ratio | 67.43 | 60.33 | 36.79 | 13.26 | 8.84 |
| Working capital ratio | 57.8% | 58.4% | 61.7% | 60.8% | 54.3% |
| Solvency | 99.1% | 99.0% | 98.3% | 94.1% | 90.7% |
| Debt / equity | 0.01 | 0.01 | 0.02 | 0.06 | 0.10 |
| Long-term debt ratio | - | - | - | 0.01 | 0.03 |
| Interest coverage | 3.86 | -14.25 | 73.30 | 316.76 | 237.09 |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| ROA | -2.6% | -3.3% | 0.1% | 20.0% | 17.3% |
| ROE | -2.6% | -3.3% | 0.1% | 21.2% | 19.1% |
| EBITDA margin | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days inventory (DSI) | - | - | - | - | - |
Balance-sheet composition 2025
Full annual accounts (24 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Balance sheet, Assets | ||||||
| TOTAL ASSETS | 20/58 | €842k | €955k | €1.12M | €1.20M | €1.17M |
| Fixed assets | 21/28 | €348k | €388k | €408k | €412k | €452k |
| Tangible fixed assets | 22/27 | €348k | €388k | €408k | €412k | €452k |
| Current assets | 29/58 | €494k | €567k | €708k | €790k | €715k |
| Amounts receivable within one year | 40/41 | €2k | €2k | €4k | €14k | - |
| Investments | 50/53 | €155k | €155k | €255k | €55k | €55k |
| Cash & bank | 54/58 | €337k | €408k | €447k | €688k | €580k |
| Balance sheet, Equity & liabilities | ||||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €842k | €955k | €1.12M | €1.20M | €1.17M |
| Equity | 10/15 | €834k | €946k | €1.10M | €1.13M | €1.06M |
| Contributions / capital | 10/11 | €13k | €13k | €13k | €13k | €13k |
| Reserves | 13 | €875k | €965k | €1.08M | €1.12M | €1.05M |
| Accumulated profits (losses) | 14 | €-54k | €-32k | €0 | - | - |
| Amounts payable | 17/49 | €7k | €9k | €19k | €71k | €108k |
| Amounts payable after one year | 17 | - | - | - | €12k | €27k |
| Amounts payable within one year | 42/48 | €7k | €9k | €19k | €60k | €81k |
| Trade debts payable within one year | 44 | €7 | €2k | €474 | €2k | €24k |
| Income statement | ||||||
| Gross operating margin | 9900 | €5k | €727 | €41k | €385k | €329k |
| Operating result | 9901 | €-27k | €-39k | €2k | €345k | €291k |
| Financial income | 75 | €5k | €8k | €2k | €206 | €280 |
| Financial charges | 65 | €369 | €95 | €535 | €1k | €1k |
| Result before taxes | 9903 | €-22k | €-31k | €4k | €353k | €290k |
| Income taxes | 67/77 | - | €414 | €3k | €113k | €87k |
| Net result for the period | 9904 | €-22k | €-32k | €932 | €240k | €202k |
| Result to be appropriated | 9905 | €-22k | €-32k | €932 | €240k | €202k |
Legal Structure
| NACE primary | Specialist medical practice(86220) |
| Legal form | Private limited company(610) |
| Incorporation | 26-09-1997 |
| Status | Active |
| Postal code | 6890 |
Real-estate footprint
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 84063A0010/00F000 | Wallonia | 2,231 m² | 1 · 147 m² | 9.8 m · 2 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2026, expected by
2026
31-08
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema · 31 days late
2025
01-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
31-12
Financial
Weakest financial yearnet €-32k ▼3493%
Net result drops to €-32k, the lowest in the series; recovery starts the following year.
31-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial
Liquidity triplescurrent ratio 36.79
Current ratio from 13.26 to 36.79; short-term debt falls from €60k to €19k.
31-08
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 31 days late
2022
31-12
Financial
Highest result since 2021net €240k ▲18.8%
Operating result €345k, net result €240k, both a record.
26-08
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 26 days late
2021
31-08
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema · 31 days late
2020
28-10
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema · 89 days late
2019
30-08
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema · 30 days late
2018
31-08
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema · 31 days late
2017
25-08
NBB filing
Annual accounts filed
fiscal year 2016 · micro schema · 25 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 6 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
Specialist medical practice86220
Names & trade names
| Legal nameFR | PAMLAB |
Similar companies
HAMEROPHTA
BE 0474.402.551 · Rochefort
DOKTER GEERT VAN DEN BROECK
BE 0466.126.966 · Brugge
Docteur Laurence THIRION
BE 0841.577.047 · Sprimont
MEDEVAL
BE 0468.961.445 · Ukkel
Dokter Tim Couvreur
BE 0644.657.743 · Roeselare